Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$9390.00
+260.00 (+2.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$102.4B
P/E
N/A
•EV/EBITDA
51.5x
↑ROE
-3.8%
↓Gross Margin
35.8%
↓Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.6%
FCF CAGR
-37.4%
FCF margin
1.5%
FCF / Net income
-0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $87.60B · net income $-2.64B · FCF $1.35B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $87.60B | $87.60B | $81.28B | $83.24B | $81.03B |
| Net Income | $-2.64B | $-2.64B | $3.79B | $83.8M | $-1.12B |
| EBITDA | $2.21B | $2.21B | $9.58B | $8.57B | $4.47B |
| EPS | -242.00 | -242.00 | 348.00 | 8.00 | -103.00 |
| Gross Margin | 35.8% | 35.8% | 43.3% | 44.4% | 43.7% |
| Operating Margin | -1.0% | -1.0% | 7.5% | 7.5% | 7.6% |
| Net Margin | -3.0% | -3.0% | 4.7% | 0.1% | -1.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.32 | 0.51 | 0.91 |
| Current Ratio | 1.14 | 1.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.35B | $1.35B | $4.24B | $2.14B | $5.53B |
| Returns | |||||
| ROE | -3.8% | -3.8% | 5.3% | 0.1% | -1.9% |
| Valuation | |||||
| P/E | — | — | 45.69 | 2943.75 | — |
| EV/EBITDA | 51.48 | 51.48 | 18.18 | 32.46 | 63.01 |
| P/B | 1.49 | 1.49 | 2.42 | 4.15 | 3.93 |
| Growth & Yield | |||||
| Revenue Growth | 7.8% | 7.8% | -2.4% | 2.7% | — |
| EPS Growth | -169.5% | -169.5% | 4250.0% | 107.8% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.3%
Start / end P/E
n/dx → n/dx
EPS bridge
348.00 → -242.00
Residual
-33.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.